Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Net Income (2016 - 2025)

iBio (IBIO) has disclosed Net Income for 16 consecutive years, with -$9.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Net Income fell 106.07% to -$9.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.7 million, a 84.3% decrease, with the full-year FY2025 number at -$18.4 million, down 94.18% from a year prior.
  • Net Income was -$9.0 million for Q4 2025 at iBio, down from -$5.7 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of -$537000.0 in Q1 2024 to a low of -$23.0 million in Q4 2022.
  • A 5-year average of -$5.8 million and a median of -$4.8 million in 2021 define the central range for Net Income.
  • Peak YoY movement for Net Income: surged 93.66% in 2023, then tumbled 805.21% in 2025.
  • iBio's Net Income stood at -$4.7 million in 2021, then tumbled by 386.15% to -$23.0 million in 2022, then surged by 83.81% to -$3.7 million in 2023, then decreased by 17.22% to -$4.4 million in 2024, then tumbled by 106.07% to -$9.0 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Net Income are -$9.0 million (Q4 2025), -$5.7 million (Q3 2025), and -$5.2 million (Q2 2025).